Breaking News

Novo Nordisk to Acquire Dicerna Pharmaceuticals for $3.3B

Gains Dicerna’s ribonucleic acid interference (RNAi) platform to develop therapies to selectively silence genes that cause or contribute to disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk has entered a definitive agreement to acquire Dicerna Pharmaceuticals for $3.3 billion. Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms applicable across Novo Nordisk’s therapeutic focus areas.   Leveraging Dicerna’s GalXC and GalXC-Plus RNAi technologies, Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease. Dicerna’s RNAi technology platform ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters